Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23473369 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
Conditions: Atherosclerosis;   Percutaneous Coronary Intervention;   Acute Coronary Syndrome
Interventions: Drug: cangrelor P2Y12 (platelet) inhibitor;   Drug: Clopidogrel - 300 or 600 mg (study arm);   Drug: Clopidogrel 600 mg post cangrelor

Indicates status has not been verified in more than two years